Baird Maintains an 'Outperform' on Pharmasset (VRUS); Year Ahead is Catalyst-Rich
Tweet Send to a Friend
Baird maintains an Outperform rating on Pharmasset, Inc. (Nasdaq: VRUS)
Baird analyst says, "On R7128, nothing can be certain until ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "On R7128, nothing can be certain until ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
